Guardant Health GH
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Guardant Health (GH) Business Model and Operations Summary
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Key Insights
Guardant Health (GH) Core Market Data and Business Metrics
Latest Closing Price
$38Market Cap
$5.04 BillionAverage Trade Volume
2,335,863 SharesTotal Outstanding Shares
123.89 Million SharesCEO
Dr. Helmy Eltoukhy Ph.D.Total Employees
2,021IPO Date
October 4, 2018SIC Description
Services-medical LaboratoriesPrimary Exchange
NASDAQHeadquarters
3100 Hanover Street, Palo Alto, CA, 94304
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Short Interest
Short Interest
This information represents bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.
Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.
Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.
Avg Daily Volume: The average daily trading volume for the stock over the specified period, typically used to contextualize short interest.
Days To Cover: The estimated number of days it would take to cover all short positions based on average trading volume.
Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Historical Stock Splits
| Execution Date | Split Amount |
|---|